Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | UGCG | Q16739 | 1/20 | 0.42 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.42 |
| ▸ | OXTR | P30559 | 2/20 | 0.42 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008849 | 0.86 | FFAR1 (0.57) | FFAR1AKR1B1ESR2ALDH1A1PTPN1 | |
| SCHEMBL9205882 | 0.83 | ALDH1A1 (0.51) | FFAR1AKR1B1ALDH1A1PTPN1 | |
| SCHEMBL4008847 | 0.82 | FFAR1 (0.60) | FFAR1AKR1B1ESR2ALDH1A1PTPN1 | |
| SCHEMBL27453802 | 0.81 | FFAR1 (0.53) | FFAR1AKR1B1ESR2ALDH1A1PTPN1 | |
| SCHEMBL6953214 | 0.80 | ESR2 (0.59) | FFAR1AKR1B1ESR2PTPN1EGLN1 | |
| SCHEMBL7791085 | 0.79 | ESR2 (0.44) | FFAR1AKR1B1ESR2ALDH1A1PTPN5 | |
| SCHEMBL6961953 | 0.79 | FFAR1 (0.54) | FFAR1AKR1B1ESR2PTPN1MME | |
| SCHEMBL11845649 | 0.78 | FFAR1 (0.50) | FFAR1AKR1B1ESR2ALDH1A1PTPN1 | |
| SCHEMBL10363262 | 0.78 | ALDH1A1 (0.59) | FFAR1ALDH1A1MME | |
| SCHEMBL23742273 | 0.78 | ROCK2 (0.55) | FFAR1AKR1B1ESR2ALDH1A1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569528-B2 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| US-20120330026-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | NOVARTIS AG (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20110184187-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | SEDELMEIER GOTTFRIED | 2011-07-28 | — | — | US | disclosed |
| US-7943647-B2 | Process for the preparation of tetrazole derivatives from organo aluminium azides | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| US-20070093542-A1 | Process for the preparation of valsartan and intermediates thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2007-04-26 | — | — | US | disclosed |
| US-7199144-B2 | Process for the preparation of valsartan and intermediates thereof | TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) | 2007-04-03 | — | — | US | disclosed |
| US-20070043098-A1 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-5587390-A | Imidazole derivatives having a II antagonist activity | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1996-12-24 | — | — | US | disclosed |
| EP-0654030-B1 | IMIDAZOLE DERIVATIVES HAVING ANGIOTENSIN II ANTAGONIST ACTIVITY | LUSO FARMACO INST (IT) | 1996-12-18 | — | — | EP | disclosed |
| WO-1994003449-A1 | IMIDAZOLE DERIVATIVES HAVING A II ANTAGONIST ACTIVITY | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043098-A1 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | ABL1, TBCA, TBC1D5 | FFAR1 3859/4885AKR1B1 1253/4885ESR2 4326/4885 |
| US-20120330026-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | ABL1, TBCA, TBC1D5 | FFAR1 3859/4885AKR1B1 1253/4885ESR2 4326/4885 |
| US-20110184187-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | ABL1, TBCA, TBC1D5 | FFAR1 3859/4885AKR1B1 1253/4885ESR2 4326/4885 |
| US-20070093542-A1 | Process for the preparation of valsartan and intermediates thereof | REN, AGT, ACE | FFAR1 2511/4885AKR1B1 131/4885ESR2 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.